Yunior Silva Barrero
General Practice · North Miami, FLNPI 1821400730
Payments from drug & device makers
Across 26 payments — averaging $32,736 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$379K
- Merck$374K
- Amgen$98K
- AbbVie$125
- Novo Nordisk$115
- SK Life Science, Inc.$113
- plus $22 from 1 others
Across 7 payments — averaging $109.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$764
What the payments were for
- Food & beverage$375100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 11 | $378,921 |
| Merck | 7 | $373,890 |
| Amgen | 4 | $97,948 |
| AbbVie | 1 | $125 |
| Novo Nordisk | 1 | $115 |
| SK Life Science, Inc. | 1 | $113 |
| Novartis | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$851,134 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 76 | $82,027 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 20 | $79,461 |
| OzempicSemaglutide | 37 | $37,589 |
| SymbicortBudesonide/Formoterol Fumarate | 143 | $34,703 |
| XareltoRivaroxaban | 21 | $27,153 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $26,752 |
| JanuviaSitagliptin Phosphate | 16 | $22,931 |
| ProliaDenosumab | 13 | $22,496 |
| LinzessLinaclotide | 21 | $16,321 |
| EntrestoSacubitril/Valsartan | 16 | $15,266 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,476 |
| CreonLipase/Protease/Amylase | 26 | $9,461 |
| Fenofibrate | 99 | $9,351 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 85 | $7,788 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 226 | $5,534 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Januvia | $373,890 | $49,68332 claims |
| Novo NordiskOzempic | $115 | $37,58937 claims |
| AbbVieLinzess, Creon, Lumigan, Synthroid | $125 | $33,41499 claims |
| AmgenProlia | $97,948 | $22,49613 claims |
| NovartisEntresto | $22 | $15,26616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.
Other general practice in North Miami
- Jose CardonaMiami$71M
- Lawrence GalitzMiami Gardens$42.5M
- Armando AcevedoMiami$15.2M
- Jorge AmayaMiami$14.2M
- Frank AlvarezHialeah$13.6M
- Hector RodriguezMiami$12.8M
- Eddie ArmasSouth Miami$12.4M
- Idalia AcostaMiami$11.4M
- Lilia Rodriguez AblesMiami$10.7M
- Jorge Monroy AvellaOcoee$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.